Halberd Corp. Develops Medication to Boost Immune System Against SARS-CoV-2 (Covid-19)

LancasterOnline
14 Jan 2021
https://lancasteronline.com/news/health/halberd-corp-develops-medication-to-boost-immune-system-against-sars-cov-2-covid-19/article_78231771-5ffe-5bd0-87ec-a01a9d114ae9.html

Dr Debra Muth at the MD Custom RX LDN Book 2 Event Oct 2020 (Low dose naltrexone) from LDN Research Trust on Vimeo.

Naltrexone a potential therapeutic candidate for COVID-19 (Abstract)

J Biomol Struct Dyn
15 Sept 2020
https://pubmed.ncbi.nlm.nih.gov/32930058/

Survey-reported medication changes among older adults during the SARS-CoV-2 (COVID-19) pandemic (Abstract)

Res Social Adm Pharm
12 Nov 2020
https://pubmed.ncbi.nlm.nih.gov/33221267/

Dickson Chemist developed a new formulation of LDN which will hopefully improve the outcomes for patients. This new formulation is a more concentrated liquid in the form of drops which are administered under the tongue and absorbed directly from the mucosal lining of the mouth. This sublingual route produces a more rapid absorption bypassing the liver and digestive tract. There are several potential advantages to this, the drug may be more effective and will not be affected by the presence of food stuffs or the hostile environment of the gut.